By using peptides to stimulate the pituitary, patients can avoid the supraphysiological spikes associated with direct HGH injections
Laugier-Hunziker Syndrome, described by Foster and Murray (2026), is the classic example
You should discuss cancer concerns with your GP or specialist before starting a GLP-1 medicine if you have: Personal history of any cancer, particularly thyroid or pancreatic malignancies Family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Previous episodes of pancreatitis Unexplained symptoms such as persistent abdominal pain, neck lumps, or difficulty swallowing Anxiety about cancer risk that may affect medicine adherence During treatment with a GLP-1 medicine, contact your healthcare provider promptly if you develop: A lump or swelling in the neck Persistent hoarseness or voice changes Difficulty swallowing or breathing Severe, persistent abdominal pain, especially if radiating to the back (seek urgent medical help via NHS 111 or A&E if severe) Unexpected or disproportionate weight loss relative to your dose and treatment plan, especially with other concerning symptoms Any other worrying symptoms It is important to maintain perspective: the proven cardiovascular benefits of GLP-1 medicines in reducing heart attack, stroke, and cardiovascular death substantially outweigh theoretical cancer concerns for most patients
If the exposure is current, having the home checked and remediated (if necessary) is a key first step
